NEWS AND ANNOUNCEMENTS
VIEW RECENT NEWS AND ANNOUNCEMENTS IN DR-TB HERE
RECENT NEWS FROM OUR JUNE 2020 NEWSLETTER
1. FDA Approves Pediatric Formulation of Bedaquiline for Multidrug-Resistant TB
Bedaquiline first received approval from the FDA in 2012 for use in adult patients. Now, the FDA has given Johnson & Johnson accelerated approval to use the drug on pediatric patients five years and older. You can access the FDA’s updated label for the drug here.
2. Tuberculosis in Children: Underdiagnosed and Undertreated
A deeper dive into comprehensive, up-to-date information on treating tuberculosis in children.
3. TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for Pretomanid as part of New Regimen
Mylan’s new Named Patient Access Program has been designed to make pretomanid accessible in countries previously lacking access to the drug.
From our May 2020 Newsletter
1. IMPORTANT NEWS: INCREASED ACCESS TO PRETOMANID/BPaL
Hope of a cure for individuals with XDR-TB.
2. WHO launches online course to improve diagnosis of drug-resistant TB
Korean patients with multidrug-resistant tuberculosis (TB) will likely get faster and better treatment than now.
3. Korea upgrades guidelines for multidrug-resistant TB
Korean patients with multidrug-resistant tuberculosis (TB) will likely get faster and better treatment than now.
EMA panel backs pretomanid for drug-resistant TB (Also from our April 2020 Newsletter)
Posted on 23 Apr 2020
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of pretomanid FGK (FGK Representative Service GmbH) for drug-resistant tuberculosis (TB).
Webinar: Hear the latest about the NiX-TB regimen for XDR-TB; Slides and Recording here!
Posted on 30 Mar 2020
On March 26, 2020, RESIST-TB hosted a webinar featuring Dr. Dan Everitt to discuss the recently published work on the NiX-TB trial, which focuses on treatment of extensively drug-resistant tuberculosis (XDR-TB). To read the publication, the article can be found below (publication #2). The presentation slides can be found below, and the recording can be found here.
WHO announces updates on new molecular assays for the diagnosis of TB and drug resistance
Posted on 16 Jan 2020
Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO).
Webinar: Advocacy for access to DR-TB treatment - webinar materials now available online
Posted on 16 Jan 2020
The TB Europe Coalition conducted a webinar on 13 November 2019 on advocating for the new guidelines on drug-resistant TB (DR-TB) treatment.
From our January 2020 Newsletter
1. Submit Feedback To Inform Overhaul of ClinicalTrials.gov
In February, ClinicalTrials.gov—the world’s largest public repository of clinical research registry and results database—will celebrate its 20th anniversary. Over the next few months, the National Library of Medicine (NLM) will be Engaging Users To Support the Modernization of ClinicalTrials.gov.
2. WHO announces updates on new molecular assays for the diagnosis of tuberculosis and drug resistance
Significant improvements to the diagnosis of tuberculosis (TB) and rifampicin resistance in adults and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO). It's easy.